

10 Sep 2018 | News

QUOTED. Sept. 10, 2018. Dave Pierce.

by

Boston Scientific is building out its urology portfolio with the addition of Augmenix Inc., developer of the *SpaceOAR* bioabsorbable hydrogel spacer for reducing the side-effects of prostate cancer radiotherapy. See what Boston Scientific MedSurg President Dave Pierce said about it here.

"The acquisition furthers our category leadership strategy in urology, and the *SpaceOAR* hydrogel is a crucial addition to our growing prostate health treatment portfolio of products that improve the quality of life and clinical outcomes for men with prostate cancer and benign prostatic hyperplasia." –Dave Pierce, president, Boston Scientific MedSurg

- Find out more: [Boston Scientific Invests In Urology With \\$600M Augmenix Acquisition](#)

[Click here](#) for a free trial of *Medtech Insight*